GSK issued a press release on July 17, 2025, announcing "that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations."
Following this news, GSK's American Depositary Receipt ("ADR") price fell over 4% on July 17, 2025.
To receive more information, please fill out the form.
